Form 4: Alkermes EVP Craig Hopkinson Reports Stock Transactions
SEC Form 4 Filing
Craig Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reports the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.
Summary
- On February 26, 2025, Craig Hopkinson, EVP R&D, Chief Medical Officer of Alkermes plc, had restricted stock units vest, resulting in the acquisition of 6,866 ordinary shares.
- Simultaneously, 3,049 shares were disposed of at a price of $34.795 to satisfy tax obligations related to the vesting of the restricted stock units.
- Following these transactions, Hopkinson directly owns 77,740 ordinary shares and 20,598 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, which carries a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency to investors regarding insider activity.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely negligible.
Key Dates
| Date | Description |
|---|---|
| 02/26/2025 | Date of transaction: vesting of restricted stock units and disposition of shares. |
| 02/28/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.